Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 9:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 102 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Atropine Sulfate Clear all
Terminated Not applicable Interventional Results available

Safety and Accuracy of Regadenoson-Atropine Stress Echocardiography in CAD

NCT00894179
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
regadenoson and atropine
Diagnostic Test
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 85 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 8, 2026, 9:53 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Side Effects of Atropine (SEA) Study

NCT03593044
View directory record Official record
Conditions
Myopia
Interventions
0.01% concentration atropine drops
Drug
Lead sponsor
Jeffrey J. Walline, OD PhD
Other
Eligibility
21 Years to 30 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Sep 8, 2026, 9:53 AM EDT
Recruiting Phase 4 Interventional

APPRAISE: Assessment of Pain and Posterior Synechiae Reduction With Atropine, an Investigation of Post-Surgical Eyes

NCT07434635
View directory record Official record
Conditions
Eye Disorders
Interventions
Atropine 1%
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 8, 2026, 9:53 AM EDT
Recruiting Phase 2 Interventional

Atropine Eye Drops for Watery Eyes (Excessive Tearing)

NCT07676981
View directory record Official record
Conditions
Epiphora
Interventions
Atropine ophthalmic solution
Drug
Lead sponsor
Rehan Ahmed
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Houston, Texas • Mesquite, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 8, 2026, 9:53 AM EDT
Not listed Phase 2 Interventional

Low Dose Atropine for Symptomatic Vitreous Floaters

NCT06174935
View directory record Official record
Conditions
Vitreous Floaters
Interventions
0.01% atropine ophthalmic drop
Drug
Lead sponsor
Jeanette Du
Other
Eligibility
19 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Reston, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 17, 2023 · Synced Sep 8, 2026, 9:53 AM EDT
Not yet recruiting Phase 2 Interventional

Evaluation of Echothiophate in Pediatric Patients With Refractory Amblyopia

NCT07554131
View directory record Official record
Conditions
Refractory Amblyopia
Interventions
Echothiophate Iodide 0.125% Ophthalmic Solution
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
3 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 8, 2026, 9:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Early Diagnosis of Diastolic Dysfunction and Reliability of DSE in Detecting Stress Diastolic Dysfunction

NCT00998205
View directory record Official record
Conditions
Diastolic Dysfunction
Interventions
Dobutamine stress echo (DSE), Atropine bolus
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Sep 8, 2026, 9:53 AM EDT
Completed Phase 4 Interventional Results available

Dexmedetomidine and Propofol in Children With History of Obstructive Sleep Apnea

NCT01344759
View directory record Official record
Conditions
Sleep Apnea, Obstructive
Interventions
Dexmedetomidine, Propofol
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Months to 25 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Sep 8, 2026, 9:53 AM EDT
Completed Phase 4 Interventional

Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.

NCT00388882
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium, ipratropium bromide / albuterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
10
States / cities
Phoenix, Arizona • Lakewood, California • Sepulveda, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Sep 8, 2026, 9:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effectiveness of Ipratropium Bromide in Preventing Exercise-induced Bronchoconstriction in Athletes

NCT01691079
View directory record Official record
Conditions
Bronchospasm, Exercise-Induced
Interventions
ipratropium bromide, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Sep 8, 2026, 9:53 AM EDT
Completed Phase 3 Interventional

An Evaluation of Treatment of Amblyopia in Children 7 To <18 Years Old

NCT00094692
View directory record Official record
Conditions
Amblyopia
Interventions
Eye patch, spectacles, atropine
Device · Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
7 Years to 17 Years
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
3
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 23, 2010 · Synced Sep 8, 2026, 9:53 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

NMBA Reversal and Postoperative Urinary Retention

NCT06948409
View directory record Official record
Conditions
Neuromuscular Blocking Agents, Urinary Retention After Procedure, Urinary Retention Postoperative, Neuromuscular Blockade Reversal Agent, Neuromuscular Blockade, Costs, Atropine, Sugammadex, Glycopyrrolate, Neostigmine, Anesthesia
Interventions
Choice of reversal agent (sugammadex or neostigmine [with muscaranic antagonist])
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
70,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 8, 2026, 9:53 AM EDT
Completed Not applicable Interventional Results available

Efficacy of Open Label Placebo in Children With FGIDs

NCT02389998
View directory record Official record
Conditions
Functional Abdominal Pain, Functional Dyspepsia, Irritable Bowel Syndrome, Functional Gastrointestinal Disorders
Interventions
Placebo Suspension, Hyoscyamine
Other · Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 21 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Sep 8, 2026, 9:53 AM EDT
Completed Early Phase 1 Interventional

Pharmacokinetics of Atropine Oral Gel

NCT05164367
View directory record Official record
Conditions
Cerebral Palsy, Sialorrhea
Interventions
Atropine sulfate gel (0.01%)
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Sep 8, 2026, 9:53 AM EDT
Completed Phase 4 Interventional Results available

A Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent Inhalation Aerosol in COPD Patients.

NCT00359788
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium, Combivent (Ipratropium/Albuterol)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Sep 8, 2026, 9:53 AM EDT
Recruiting Phase 4 Interventional

Comprehensive Esophageal Diagnostics Study

NCT04641702
View directory record Official record
Conditions
Achalasia
Interventions
Atropine challenge, Esophageal muscle biopsy
Drug · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 8, 2026, 9:53 AM EDT
Completed Phase 2 Interventional Results available

PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01350128
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
PT001 MDI, Ipratropium Bromide HFA Inhalation Aerosol, Placebo MDI
Drug · Other
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
8
States / cities
Panama City, Florida • Winter Park, Florida • Cherry Hill, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Sep 8, 2026, 9:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

NCT02858310
View directory record Official record
Conditions
Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ, Vulvar Neoplasms, Vulvar Diseases
Interventions
E7 TCR cells, Aldesleukin, Fludarabine, Cyclophosphamide, EKG, Biopsy, Chest CT and MRI or PET, PFT, Granisetron, Ondansetron, Droperidol, Prochlorperazine, Diphenoxylate HCL, Atropine sulfate, Codeine sulfate, Loperamide, Indomethacin, Acetaminophen, Diphenhydramine HCL, Hydroxyzine HCL, Meperidine
Biological · Drug · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
Bethesda, Maryland • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 8, 2026, 9:53 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Dropless Pars Plana Vitrectomy Study

NCT05331664
View directory record Official record
Conditions
Rhegmatogenous Retinal Detachment
Interventions
Pars plana vitrectomy, Triamcinolone Acetonide 40mg/mL, Moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin, Prednisolone 1%, Atropine 1%
Procedure · Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
40 Years and older
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 8, 2026, 9:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Influence of Atropine on Choroidal Thickness

NCT03158142
View directory record Official record
Conditions
Myopia
Interventions
Atropine Sulfate 1% Oph Soln
Drug
Lead sponsor
State University of New York College of Optometry
Other
Eligibility
18 Years to 40 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2018 · Synced Sep 8, 2026, 9:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Adverse Events Related to Low Dose Atropine

NCT05683535
View directory record Official record
Conditions
Myopia, Progressive
Interventions
Atropine Sulfate
Drug
Lead sponsor
Scripps Health
Other
Eligibility
Not listed
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Sep 8, 2026, 9:53 AM EDT
Completed Phase 2 Interventional

Revefenacin in Acute Respiratory Insufficiency in COPD

NCT04315558
View directory record Official record
Conditions
COPD, Acute Respiratory Failure
Interventions
Revefenacin Inhalation Solution [Yupelri], Ipratropium Bromide
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
40 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Los Angeles, California • Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Sep 8, 2026, 9:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

(Study: Vertex IIS) Does Ivacaftor Alter Wild Type CFTR-Open Probability In The Sweat Gland Secretory Coil?

NCT02310789
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor, β-Adrenergic cocktail, Pilocarpine Nitrate 5%, Macroduct sweat stimulator
Drug · Device
Lead sponsor
Richard Barry Moss
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Sep 8, 2026, 9:53 AM EDT
Completed Phase 3 Interventional

Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia

NCT00000170
View directory record Official record
Conditions
Amblyopia
Interventions
Atropine, Eye Patch
Drug · Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
Up to 6 Years
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Sep 8, 2026, 9:53 AM EDT